India's worst-performing stock in July may rebound if history is any guide

When that’s happened over the past five years, shares of the Hyderabad-based company have rallied about 15% on average in the 20 subsequent trading sessions, according to data compiled by Bloomberg | Photo: Bloomberg
Dr. Reddy’s Laboratories Ltd., one of India’s largest drug firms, is the nation’s worst-performing stock in July on disappointing earnings and a US probe. But one technical indicator suggests the shares could be due a snap back.

The stock’s relative strength index has dropped to a level indicating the shares are oversold. When that’s happened over the past five years, shares of the Hyderabad-based company have rallied about 15% on average in the 20 subsequent trading sessions, according to data compiled by Bloomberg.

Dr. Reddy’s earnings trailed estimates and the company has disclosed that it’s responding to a subpoena from the U.S. Securities & Exchange Commission. Jefferies India Pvt. analyst Abhishek Sharma, who rates the stock a buy, said in a note the SEC probe “could be material” if it leads to an adverse finding, but shouldn’t affect “our thesis on the company.”

The drug-maker’s shares became oversold 12 times over the past five years based on the relative strength index. In 55% of the cases they traded higher over the next 20 days, according to the data compiled by Bloomberg. In the instances where they were lower, the average loss was just over 6%.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel